Study of all data on Roche's highly debated Tamiflu says it does help

A significant new study of Roche's ($RHHBY) blockbuster flu fighter Tamiflu has found that, while it has side effects, it can reduce symptoms by a day and keep some patients out of the hospital with complications, Reuters reports. The drug, which was heavily stockpiled by governments during a swine flu scare in 2009, has been hotly debated with contentions that it just doesn't do much. The new analysis, published in The Lancet on Friday, evaluated the data from all previously published and unpublished trials of Tamiflu. Story | More

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.